ロード中...
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
BACKGROUND: To investigate the long-term efficacy and safety of empagliflozin monotherapy compared with placebo and sitagliptin in drug-naïve patients with type 2 diabetes mellitus. METHODS: Of 899 patients randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, placebo, or sitagliptin 100 m...
保存先:
| 出版年: | Cardiovasc Diabetol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4690334/ https://ncbi.nlm.nih.gov/pubmed/26701110 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-015-0314-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|